BioMed Valley Discoveries: BioMed doses first subject in Phase II gastrointestinal malignancy trial

Being developed as a new anti-cancer drug, ulixertinib is a small molecule, extracellular, signal-regulated kinase inhibitor. The post BioMed doses first subject in Phase II gastrointestinal malignancy trial appeared first on Clinical Trials Arena.